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Abstract
Therapy of allergic diseases in children implicates avoidance of allergens, standard phar-
macotherapy, and immunotherapy. Immunotherapy is the only treatment for allergic 
diseases with the ability to change the natural course of the disease, thus stopping its 
further progression as well as the development of new allergic diseases and new sensi-
bilizations. The objective of this chapter is to give insight into the latest data on immu-
notherapy in treating children with allergic diseases. Methods: The study involved a 
search for relevant articles on the MEDLINE and PubMed up to 2017. Results: Numerous 
studies have shown that the sublingual application of allergen-specific immunotherapy 
is adequate, safe, and efficient in the therapy of immunoglobulin E (IgE)-mediated aller-
gic diseases of the respiratory tract in children, but there are still some questions to be 
solved concerning the usage of SLIT in children younger than 5 years old, SLIT for poly-
sensitized patients, duration of SLIT, long-lasting effects of SLIT. Conclusions: In order 
to improve the clinical efficacy of SLIT, we are looking for new routes of administration, 
new allergens, new protocols as well as combination of SLIT with other immune modula-
tory treatments.
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1. Introduction
1.1. Epidemiology of asthma and rhinitis
With a global prevalence of 6.9% (ranging from 3.8 in Asia-Pacific and Northern and Eastern 
Europe to 11.3% in North America), asthma is one of the most common chronic diseases 
in children, adolescent, and adults [1]. The prevalence rate of allergic rhinitis, asthma, 
and eczema in Serbia has been investigated as a part of the International Study of Asthma 
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and Allergies Phase Three. The study included around 14,000 from 5 regional centers differ-
ent geographical and urban characteristics (children both from urban and rural areas par-
ticipated). Investigators analyzed the prevalence of allergic diseases in two age groups (the 
first one preschool children aged 6–7 years old and the second one children between the age 
of 13–14 years old. The prevalence of asthma was 6.59% in younger age group, whereas 
the prevalence in older age group was around 5.36%. Note that 7.17% of preschool children 
and 14.89% of school children were diagnosed allergic rhinitis. Overall, asthma prevalence 
was 5.91%, rhinitis 11.46%, and eczema  14.27%  [2]. The growing worldwide burden of aller-
gic diseases is properly defined as the “allergy epidemic.” The German epidemiological 
Multicenter Allergy Study (MAS) suggested an age-related evolution of atopic and allergic 
diseases, usually named “atopic march.” In fact, on epidemiological bases, infantile eczema 
and food allergy usually precede the onset of allergic airway disease (rhinitis and asthma). 
It is also interesting to point out that unlike other common chronic diseases such as diabetes 
mellitus or hypertension, it is well established that the development of allergic diseases start 
just after birth or according to some authors maybe earlier in prenatal period [3]. The inci-
dence of asthma is the highest in preschool and early school age with an improvement 
in symptoms and a decrease in prevalence afterwards, but with one more pic in incidence 
in adolescents’ period especially in female teenagers mainly due to hormone disturbance. 
It is well known that allergic diseases are multi factorial which means that in their patho-
physiology both genetic and environmental factors are included. Atopic family history is 
one of the most important risk factors for the development of asthma. MAS cohort study 
analyzed the main risk factors for persistent asthma/wheeze in an early adolescent’s period. 
According to the results from this huge study wheezing before the age of 3 as well as wheez-
ing after the age of 6, accompanied with early atopic dermatitis, positive family history of 
atopic diseases and positive allergy tests, particular to perennial allergens represent the main 
risk factors [4, 5].
Although according to birth cohort studies data we are aware that genetic burden has 
an important influence in allergies development and despite lots of efforts, we have still failed 
to identify responsible genes. Many factors in the environment contribute to the develop-
ment of allergies (e.g., diet, immunizations, antibiotics, pets, and tobacco smoke), but we do 
not know how to modify the environment to reduce the risks [6]. According to several epide-
miological studies, a decline in microbial diversity was proposed to have an important role 
in allergic epidemic, best summarized in hygiene hypothesis, and nowadays defined as “bio-
diversity hypothesis.” Identification of prenatal and early postnatal risk factors is of a great 
importance for early prevention and successful intervention. Two recent studies showed that 
reduce food diversity in early childhood can be associated with atopic sensitization and allergic 
diseases later on. It is also suggested that high “antigen burden” in early life can be a pro-
tective factor necessary to “educate” the immune system and to prevent childhood allergic 
diseases. Early allergy prevention that includes: administrations of probiotics to pregnant 
mothers and to high-risk children, oral or intranasal extracts, and earlier introduction of foods 
is still matter of a debate due to conflicting results [7, 8]. Despite many different options are 
currently available for the diagnostic workup and management, the burden of allergic airway 
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diseases still represents a major health problem in childhood. It is a very well known that 
allergic diseases are multifactorial in terms that both genetic and environmental and risk fac-
tors are involved in its pathogenesis. Taking about different endo- or phenotype is very com-
mon when we analyze these diseases. Looking for a better quality of life (QOL) and disease 
of overall morbidity and mortality rate seek further investigation on every single individual 
risk factor that can have even the smallest impact on the disease development. Searching 
for a new and more individualized treatment for allergic diseases most of current research 
is focusing on the identification of biological and clinical predictive markers of allergy 
and asthma onset [9].
2. Diagnostic tools and monitoring
Despite many different diagnostic tools for allergic disease it  still remains a challenge espe-
cially in infants and toddlers. Skin tests represent an important diagnostic tool in workup 
of many allergic diseases. These tests are mainly used for the diagnosis of inhalant aller-
gies, but nowadays there are more and more tendencies to use this kind of tests for allergies 
to food, venom, occupational agents, and drugs. Skin prick tests (SPTs) and intradermal tests 
still represent the cornerstone of the diagnosis of IgE-mediated (type I) allergies. They are 
easy to perform, cheap and allow a fast reading, usually performed in outpatient clinics. 
Performing skin prick tests needs a specific training, especially for intradermal and epicu-
taneous tests with nonstandard allergens, that are not usually performed in children pop-
ulation. Special precautions that have to be considered before performing skin prick tests 
include the usage of some drugs, skin conditions and in adolescents and adults pregnancy. 
Before performing in vivo skin prick tests patients are not allowed to take drugs such as anti-
histamines at least several days because it is well known that these kinds of drugs could 
mask positive results of type I reactions, on the other side conditions like pressure urticaria 
or dermographism are able to provoke false positive results. For that reason using positive 
control histamine and negative control saline solution are crucial for results interpretations. 
Skin prick tests (SPT) are one of the most important diagnostic tools in asthma and AR diag-
nosis with sensitization to inhalant allergens. They can get prompt information on sensitiza-
tion to inhalant allergens such as pollen, house dust mites, pets, to a lesser extent molds. 
Recommendation for SPTs is available with more or less variation in many climate and geo-
graphical areas. As they are very cheap and easy to perform SPTs are of a great importance 
especially in undeveloped or developing countries. Here, it is also interesting to mention 
that in tropical areas standard SPTs battery should include typical tropical allergens such 
as Blomia tropical. In southeastern and Western Europe standard allergens for preform-
ing SPTs usually include following allergen solutions: tree, ragweed, and grass pollen, 
house dust mite, molds, cockroach, dogs, and cats dander. Before starting allergen-specific 
immunotherapy SPTs have to be performed [10–14]. Nasal and bronchial provocation test 
are indicated for patients with typical clinical symptoms and signs of allergic rhinitis and/
or asthma but with negative in vivo skin prick tests [15]. Those tests should be performed 
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exclusively by a well-trained staff at the allergy departments. They are very important for 
distinguishing allergic and nonallergic rhinitis as well as for the diagnosis of local allergic 
rhinitis (LAR)—typical clinical history of allergic rhinitis with positive nasal provocation 
test, usually with elevated eosinophils in nasal smear, but with negative skin prick or/and 
in vitro allergy tests [16]. In vitro allergy tests are cornerstone of allergy diagnostic especially 
in the pediatric population. All children with positive clinical history of allergic diseases 
(atopic dermatitis, allergic rhinitis, and/or asthma) should be evaluated, particularly those 
with positive uni- or bilateral family history of atopic diseases. Determinations of total IgE, 
followed with evaluation of the allergen-specific antibody levels are precede the introduction 
of allergen-specific immunotherapy. It is also a very important to be mentioned that the inter-
pretation of the allergy tests should be strictly done in the light of clinical history of a certain 
patients. Novel diagnostic tools are also capable to determine sensitization to a specific pure 
or recombinant allergens that is of a great importance for individualized treatment approach. 
Sometimes this kind of tests are the most relevant to confirm the diagnosis of allergy sen-
sitization. To data, the most commonly used system to determine allergen-specific IgE is 
the ImmunoCAP system that are considered as a goal standard for in vitro diagnosis of aller-
gen condition. Despite great technological improvements in in vitro diagnostics of allergies, 
several problems still remain. Although elevated IgE is a marker of IgE-mediated allergy, 
this is not sufficient for the induction of symptoms. According to the data, more than 20% 
of patients with elevated IgE are in fact asymptomatic. Elevated serum IgE level is irrel-
evant as long as it does not bind to Fcέ receptors on effectors cells (mastocytes, eosinophils, 
and basophils). Positive allergen-specific IgE in serum is not sufficient to confirm allergy 
in all cases [17–19]. At the current state of art it is a very important to be a little bit septic about 
allergy diagnostic test results only based on determination of allergen-specific serum IgE 
levels and to consider clinical history, accompanied  by adequate skin prick tests or provo-
cation tests, which drive the diagnosis before considering allergen-specific immunotherapy 
inclusion. During the last decades, there has been a huge improvement in in vitro allergy 
diagnosis due to novel approaches that include molecular components. It has been already 
mentioned that allergen-specific tests are not enough sensitive and specific for allergy diag-
nosis, through the advent of molecular technology, some weaknesses, and shortcomings 
of classical approach that used only natural extracts could be solved. Component resolved 
diagnosis (CRD) of the specific IgE response provides more individual approach in diagnosis 
of allergic patients and better selection of patients for allergen-specific immunotherapy. It is 
also of a great value for monitoring of the efficacy, immunogenicity and safety of allergen-
specific immunotherapy [20, 21]. Cellular allergy testing represents one more in vitro allergy 
diagnostic tool. It expands the tools of allergist to diagnose and monitor allergic diseases. 
The basophil activation test (BAT) is the most common used cellular allergy tests in routine 
clinical practice and in research. That test is able to document type I sensitization to a specific 
allergen, as fraction of blood basophils activated by soluble allergen. Basophil sensitivity 
can be used for identification the main sensitizer among cross-reacting allergens or allergen 
preparation as well as for monitoring progress of allergen-specific immunotherapy and anti-
IgE therapy [22–24].
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3. Biomarkers and prediction
Determination of a certain biomarkers that are known to be important in pathophysiology 
of allergic diseases can be a very useful in primary prevention, early intervention and dis-
ease course modification [25]. Currently reliable tools that can adequately predict which 
children will develop asthma are still lacking [26]. Nowadays identification and determina-
tion of biomarkers in diagnosis of allergic diseases represent an important step toward better 
understanding of a great number of different endotypes. Biomarkers are also very impor-
tant for increasing drug effectiveness through a more individualized  therapeutic approach. 
Discovering novel biomarkers or combining them with the existing one and better under-
standing of different asthma endo- and phenotypes are important goals in allergy research 
improving both allergy diagnosis and treatment [27–29]. Fractional exhaled nitric oxide 
FeNO is considered a very good biomarker of eosinophilic inflammation of lower airways. 
Many data showed that FeNO is a reliable predictor of corticosteroids responsiveness [30]. 
The results form the most recent studies indicated that allergen-specific immunotherapy has 
also an impact on the decrease of eosinophilic airway inflammation [31]. Periostin is a down-
stream molecule of interleukin (IL)-4 and/or IL-13 has been recently marked as a surrogate 
biomarker of type 2 inflammation and tissue remodeling in bronchial asthma. It has been 
shown that serum periostin can predict the efficacy of anti-IL-13 antibody (lebrikizumab) 
and anti-IgE antibody (omalizumab). Sputum eosinophils are useful for estimating the effi-
cacy of anti-IL-5 antibody (mepolizumab) [32, 33].
4. Therapy of allergic airway disease in childhood
Although there are numerous studies, management of allergic disease is still a matter 
of a debate. According to the data management of allergic diseases, consider avoidance 
of the risk factors, treatment, and induction of tolerance. In that light the management of aller-
gic diseases depends on how easy is to avoid the triggers, whether there are multiple triggers 
and how easy is to induce tolerance. The possibility to avoid certain allergen mainly depends 
on the nature of that allergen. For ubiquitous allergens such as house dust mites or pollens 
it is usually impossible to avoid, unlike for animal dander [34]. There are also some studies 
suggest that food allergen avoidance in pregnancy, lactation, and infancy have preventive 
role in the development of food allergy, and possibly other allergic diseases. The only current 
recommendations to prevent allergic disease are exclusive breastfeeding at least 4–6 months 
and if breastfeeding is insufficient or not possible, hypoallergenic formula for the high-risk 
infants [35–37]. The most common approach used in allergic diseases treatment is symptom-
atic therapy in step management strategies. Pharmacologic therapy is tailored to the primary 
symptom or symptoms and to the severity of symptoms without modifies the long-term out-
come of allergy. The optimal utilization of pharmacologic therapies varies among regions 
and countries and varying preference of therapies in different populations [38, 39]. According 
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to the clinical data, more targeted therapies include monoclonal antibodies against IgE 
and against various proallergic cytokines (e.g., anti-IL-5, anti-IL-13, and anti-IgE). Although 
expensive, these therapies are useful in the management of selected patients who are usually 
unresponsiveness to standard pharmacological treatment [40].
5. History of sublingual allergen-specific immunotherapy
Although all story of immunotherapy seems to be a new one, the first routes of immu-
notherapy dates back to 1911 when two English researchers used water solution of hay 
fever pollen extracts for treating hypersensitized patients. They noticed that hypodermal 
inoculation of specific allergen could have some benefit. Without a sound knowledge 
of basic and clinical immunology immunotherapy was pure empiric, not so widely used 
treatment for decades [41, 42]. The second very important step in the history of sublin-
gual immunotherapy was the findings of a group of German researchers who showed 
that sublingual route of allergen-specific immunotherapy could be equally clinical effec-
tive as subcutaneous route [4, 43]. They performed a small double-blind placebo control 
crossover trail. The maximum subcutaneous tolerated dose of a house dust mite (HDM) 
extract was given sublingual as drops three times daily [44]. They showed an improvement 
in symptoms and improvement in nasal inspiratory peak flow. A few years later Scadding’s 
and Brostoff proved a clinical efficacy of low dose sublingual immunotherapy in patients 
with allergic rhinitis sensitized to house dust mites in a double-blind placebo-controlled 
trial (DB-PCT) [45] whereas Italian allergist were the first one who showed clinical efficacy 
of SLIT for patients with allergic rhinitis and/or asthma sensitized also to house dust mites. 
Those study included both adults and children population [46]. In early 1990s, the first 
commercial available sublingual immune drops were developed. Since the introduction 
of sublingual immune drops, the scientific community has been seeking for improvement. 
When evaluating the findings from clinical trials with sublingual immunotherapy drops, 
it became clear that this therapy was more likely to be effective when administered once 
daily and higher doses. Moreover, pharmacokinetic studies of SLIT showed that only 
a very small proportion of liquid extracts was taken up into superficial layer of sublingual 
mucosa. Searching for a way to augment local allergen uptake sublingual rapidly dissolv-
ing tablets were developed. These tablets facilitated the delivery of high concentration 
of allergen in a small volume. This concept led to the clinical and commercial development 
of high-dose sublingual AIT using fast-dissolving tablets [47]. Early papers with sublin-
gual allergen immunotherapy demonstrated positive results, and in 1993, the European 
Academy of Allergy and Clinical Immunology was the first official organization to rec-
ognize that sublingual administration could be a “promising route” for allergic desen-
sitization. Two studies from 1999 to 2001 showed a satisfied safety profile of sublingual 
route for both children and adults [48–51]. From 1998, the World Health Organization 
recommended SLIT as an “a viable alternative to the injection route in adults” [52]. Wilson 
Cochrane review from 2003 analyzed 49 randomized control trials (RCTs) with 4589 chil-
dren and adults affected by allergic rhinitis (with or without asthma or conjunctivitis) 
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and proved clinical efficacy of SLIT over placebo [53]. To date, over 70 double-blind, pla-
cebo-controlled trails and several meta-analyses of sublingual allergy immunotherapy 
drops have been reported. It is important to note that many trails with SLIT drops or tab-
lets were small and/or had an open label design. Over the last 10 years, however, several 
adequately designed and powered trails have been conducted with grass pollen, as well 
as with Dermatophagoides pteronyssinus (DP) in both adults and children, and have dem-
onstrated efficacy and safety with this therapeutic approach [10, 54].
6. Clinical efficacy of SLIT still matter of a debate
Although a great number of various meta-analyses and DB-PC-RCTs have showed clinical 
efficacy of SLIT in children population diagnosed allergic rhinitis and/or asthma [55], due to 
significant clinical and methodological heterogeneity, some issues are still a matter of debate. 
One of the main issues to be solved is long-term efficacy, particularly after cessation of the treat-
ment. Results from several European clinical trials in pediatric and adult patients with grass 
pollen-induced rhinoconjunctivitis have shown that grass AIT reduces daily rhinoconjunc-
tivitis symptom scores compared with patients receiving only symptomatic medications. 
The proportion of days with minimal or no symptoms increase in patients on SLIT. The same 
study also showed the improvement of quality of life in children on SLIT. The beneficial 
effects were observed for three consecutive years of treatment as well as during the first year 
following cessation period, indicating a disease modifying effect and persistence of efficacy 
despite discontinuation of therapy [56–60]. Due to the fact that majority of atopic patients 
are poly sensitized, one of the most important issues to be answered is SLIT efficacy in those 
patients. Recent study confirmed clinical efficacy of SLIT in reducing nasal and ocular symp-
toms and the use of rescue medications, also observed no differences in clinical efficacy 
in mono- and poly-sensitized patients [61]. However, the cross-protection against unrelated 
allergens seems to be limited [62]. Although it passed more than a decade of proven clini-
cal efficacy of SLIT, data of long-lasting effects are still missing. Results from a 15-year-long 
prospective study by Marogna et al. [63] show that long-lasting effects of SLIT are in direct 
correlation with the treatment’s duration. Some study suggested that 4 years of SLIT may 
be associated with more favorable effects than 3 years of treatment [64]. As the only immune 
modulatory treatment for allergic diseases, preventive role of AIT is of a great interest. Some 
authors are very doubtful concerning the adherence and tolerability of the treatment par-
ticularly in the pediatric population [65], whereas the other one claimed that even 1 or 2 
years of treatment is sufficient to mediate immunological response [66, 67]. The second 
important issue on SLIT is long-lasting effects. After a 12 years of follow-up period Eng 
et al. showed preventive effects of SLIT 6 years after the treatment termination comparing 
with the standard pharmacotherapy [68]. Although the best candidates for allergen-specific 
immunotherapy are mono sensitized patients Malling et al. in their study showed that desen-
sibilization with the predominant allergen in polysensitized participants can be similar effec-
tive [69]. In the light of preventive effects of immunotherapy and possibility to have impact 
on further evolution of allergic diseases (atopic march), the opportunity to use this kind of 
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treatment in very young children is of a great importance, but several issues have to be answered 
[70–72]. Immunotherapy can overcome problems related to the long-term pharmacotherapy 
[73], adherence and compliance to the standard treatment. Low-adherence and bad compli-
ance to a long-term pharmacotherapy, both drug (problems with the usage of inhaled drugs) 
and non/drug-related factors can be overcome with the introduction of immunotherapy. All 
chronic diseases have an impact on quality of life due to high score of school absenteeism, 
impaired school performance, frequent emergency unit visits. Children with allergic diseases 
especially those with asthma showed low physical activity performance [74, 75]. High level 
of anxiety as well as higher incidence of depression and other physiological disorders can 
be seen in children and adolescents with asthma, allergic rhinitis and atopic dermatitis. A 
certain number of studies confirmed the impact of SLIT on all previous mentioned aspects of 
quality of life  [76, 77].
7. Safety and tolerability of SLIT in allergic children
Over the last 20 years, sublingual allergen immunotherapy has gained popularity based 
on controlled trails that have demonstrated a favorable safety profile [78, 79]. Although 
a great number of DB-PC-RCT showed clinical efficacy of SCIT since the British Committee 
on Safety of Medicines in the UK reported 26 SCIT-related anaphylactic deaths between 1957 
and 1986, the interest for alternative routes constantly grows. The risk of subcutaneous immu-
notherapy (SCIT)-related systemic adverse events (SAEs) still represent a major concern that 
may, sometimes limit the use of this effective treatment, especially in the pediatric popula-
tion. On the other side the overall safety of SLIT has been widely proven and accepted [80]. 
Moreover, Nichani study showed that SLIT can be safely administered to patients who previ-
ously experienced systemic reactions in response to subcutaneous allergen immunotherapy.
According to double-blind placebo-controlled-randomized clinical trials (DB-PC-RCTs) 
for allergic asthma, allergic rhinitis or allergic rhinoconjunctivitis [80–84] and real-life stud-
ies only several life-threatening and nonlife-threatening severe systemic reaction related 
to SLIT are reported [50, 85–87]. Overall prevalence of systemic adverse events was lower 
than 20% in DB-PC-RCT, whereas the prevalence of severe systemic reactions was between 
1 and 2% of total recorded events [88–93]. Most commonly postmarketing surveys reported 
mild to moderate usually self-resolved systemic reactions [94, 95]. A very important issue 
concerning SLIT particularly in the pediatric population is to define risk factors for devel-
oping systemic reactions. Up to now several potential risk factors are defined: inadequate 
administration conditions (use of non-standardized extracts, administration of products con-
taining a mixture of many allergens, overdosing [92]), and/or patient-related nonspecific risk 
factors (include cardiovascular diseases and long-term therapy with noncardioselective beta-
blockers) that are very uncommon in children [96]. Those conditions are considered as special 
precaution, but not contraindication for SLIT introduction. On the other side uncontrolled 
asthma or severe asthma, oral lesion, or acute infections can represent temporary contraindi-
cation for SLIT. Although previous systemic reaction due to SCIT were considered as absolute 
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contraindication for all kinds of immunotherapy, results from recent studies showed that they 
do not represent risk factors for further usage of other kinds of ASIT including sublingual 
[96]. Local adverse reactions are most common SLIT-related side effects although it is not very 
easy to record them as it is not usually including in postmarketing analysis nor in DB-PC-RCT 
[50, 85–88]. Its prevalence varies from 50 to 80% and they include oropharyngeal and gastro-
intestinal reactions such as itching, pruritus, and eczema in oral mucosa and/or diarrhoea, 
vomitus, and abdominal pain [97–99].
The second issue that is also of a great importance is a matter of tolerability that can have 
a great impact on overall clinical outcomes [100]. Both systemic and local adverse events may 
have influence on treatment discontinuation as they are most common after the first adminis-
tration. In order to improve adherence clinicians should be well educated and trained to rec-
ognize local and systemic adverse events and to give also patients adequate explanation how 
to deal with them, although SLIT has much better safety profile compared with subcutaneous 
allergen-specific immunotherapy. WAO proposal on grading local adverse events can help 
to achieve better tolerance and adherence [96].
8. Quality of life studies
According to many DB-PC-RCT, real-life studies and meta-analysis quality of life (QOL) is 
a very important issue for children and adults with allergic diseases. As it has been already 
mentioned, their quality of life is not so often satisfied particularly in school-aged period 
[101]. Standard pharmacotherapy treats only symptoms but not the disease itself, nor 
the quality of life. Although lots of studies proved clinical efficacy of SLIT, only a small 
part of them take QOL in consideration. One of them is Ciprandi et al. study [102] that has 
showed the improvement of QOL in polysensitized patients with AR and/or asthma treated 
with SLIT. Bousquet et al. study of DB-PC-RCT proved that patients on SLIT had a better QOL 
compared with the group of patients on placebo [103]. However, the results from the stud-
ies are controversial. While Bousquet et al. and Ciprandi et al. showed the improvement 
of the QOL in SLIT groups, Khinchi et al. found no statistical significant difference in QOL 
scores among three groups, that is, SLIT, SCIT, and placebo, using a 36-item short-form health 
survey (SF-36) questionnaire [104].
9. Oral tolerance
The mechanism of action of the allergen-specific immunotherapy is very complicated 
and still remained unexplained. For an easier understanding of the mechanism of action 
of ASIT, we divided the immune response to early and late immunological response. 
In the early phase of immunotherapy (induction phase) there is a decrease in the num-
ber of tissue mast cells, eosinophils and basophils followed by a decrease in the release 
of their cell mediators [105]. Reduction of the number of basophils induced by the oral 
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regulation of the H2 receptor leads to the inhibition of FcεRI-mediated histamine sup-
pression and other mediators. In the first phase of the immune response, the synthesis 
of IgG4 and IgA is increased [106]. IgG4 blocks the interaction of IgE and allergens as well 
as the presentation of allergen to T cells. In the late phase, after one to several months, 
the immune response from Th2 to Th1 is reoriented, as well as the increase in the number 
and function of both types of T-regulatory cells (T-reg): natural (nT-reg) and inducible 
(iT-reg) [107]. iT-reg originated from naive CD4+ T lymphocytes and they are the most 
important source of IL-10, which is an important factor in peripheral tolerance [108, 
109], because it inhibits IgE production from one, and on the other hand stimulates IgG4 
secretion and in this way directly inhibits the activity of allergen-specific T lymphocytes 
[110]. The nT-reg cells (CD4+, CD25+ and FOXP3+ (Forkhead box protein 3)) are thymus 
origin and exhibit synergistic effects with iT-reg cells [111] exposing high levels of IL-10 
and TGF-beta [112]. T-reg stimulates the proliferation and differentiation of IL-10-secreting 
dendritic cells, which have a crucial role in the activation and differentiation of different 
subtypes of T cells. Reducing the number of cell mastocytes, eosinophils, and basophils, 
increasing IgG4 and IgA synthesis, re-orientation from Th2 to Th1, increasing the num-
ber, and function of IL-10 producing T-reg cells play a significant role in the development 
of immune tolerance and long-lasting immunotherapy effect on the overall immune func-
tion and on the immune response to allergens [113–116].
10. Future perspectives
As it mentioned above clinical efficacy of immunotherapy has been proven in a great num-
ber of clinical studies but there are still some issues to be discussed. Recent studies are 
more focused on the usage of recombinant allergen-based immunotherapy that will pos-
sible makes allergy vaccines more safe, convenient, and effective. Recombinant-allergen 
vaccines also contain defined amounts of the allergen components, and the composition 
can be tailored according to patient’s sensitizations. Both recombinant allergen-diagnostic 
tests and immunotherapy lead to more personalized and stratified treatment of different 
allergic entities. Recombinant allergen-based vaccines have been developed and success-
fully evaluated for several respiratory allergen sources including food allergies [117–120]. 
The second approach for minimizing side effects and improves compliance is the usage 
of peptide immunotherapy that has been proven in many studies as effective in treating 
patients with different respiratory allergies [121]. Data from the studies showed that this 
kind of immunotherapy is clinical effective for months to years after a short course of treat-
ment. Some studies also investigate new routes of administration such as intralymphatic 
and epicutaneous. Although it is proven as safe and efficacy, both routes require further 
clinical investigation [122, 123]. Recently, scientists have exploited the immune system 
to produce antibodies from single B cell clones, heralding the era of monoclonal antibod-
ies. Biological agents (biologicals or biologics) bring revolution in the treatment of many 
rheumatic and immunological disorders and are currently being assessed for allergic dis-
orders. Better understanding the endotypes and phenotypes of allergic disease may lead 
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to specifically targeting the responsible molecular mechanism by a biological. The mecha-
nism of biologicals implies the inhibition of a specific molecule involved in allergic inflam-
mation, without weakening immunity against viruses and bacteria. The design and use 
of biologicals requires a profound understanding of the mechanisms underlying allergy. 
Several biologicals are being assessed in clinical trials, including biologicals inhibiting inter-
leukin (IL)-4, IL-5, IL-9, IL-13, and immunoglobulin E, but most of them are still being tested 
in clinical trials, involving patients with allergic asthma, allergic rhinitis, food allergy, urti-
caria, atopic eczema, and diseases with high eosinophil counts. It is to be expected that 
biologicals will replace or reduce the use of the currently prescribed unspecific pharmaco-
therapy of allergic inflammation. Better understanding of disease endotypes, identification 
of novel biomarkers, and discovery of novel biologicals are the cornerstones of the modern 
approach in treating allergic diseases [124–127].
11. Conclusion
According to a great number of clinical studies, allergen-specific immunotherapy in com-
bination with asthma and anti-allergic medication is clinically effective in treating children 
with respiratory allergies. Respecting the newest data, SLIT can be used not only in chil-
dren with stable asthma, but also in those with uncontrolled asthma but then in combination 
with anti-IgE-omalizubam treatment. AIT in children can even bring more benefits. At first, 
data suggested that SLIT reduced the usage of corticosteroids that can have deep negative 
impact on child development. The second benefit is the possibility of AIT to change the natu-
ral course of allergic diseases in terms of asthma prevention in children with allergic rhini-
tis. The problem of SLIT, especially in the young population of children and adolescents, is 
compliance that can be possibly overcome with the introduction of ultra-rush and rush pro-
tocols. Investigating the various effects of immunotherapy based on the developmental stage 
of children and adolescents can help to identify the optimal dose, frequency, treatment dura-
tion, and age for starting to treatment. Better selection of well responders based on endotype-
driven approach is expected to increase both efficacy and safety.
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